Intestinal microbiota: the new target for the treatment of postmenopausal osteoporosis

Xiaoyue JIA,Liwei ZHENG,Quan YUAN,Xuedong ZHOU,Xin XU

DOI: https://doi.org/10.3969/j.issn.1006-7108.2017.03.023

2017-01-01

Abstract:Postmenopausal osteoporosis is a bone metabolic disease characterized by bone loss and structural destruction,which is induced by estrogen deficiency and leads to an increased frequency of fracture in postmenopausal women.Postmenopausal osteoporosis has attracted increasing attention due to its high morbidity and serious complications nowadays.Current medications of postmenopausal osteoporosis are accompanied with many side effects,sometimes even causing disorders of the organs and systems.Hence,it is imperative to seek a new approach both safe and effective for the treatment of postmenopausal osteoporosis.The intestinal microbiota is the collection of all microorganisms colonized in the gastrointestinal tract,and a probiotic is a dietary or medical supplement consisting of beneficial intestinal bacteria.Current studies have revealed the close relationship between intestinal microbiota and bone remodeling or bone metabolic diseases.The significant efficacy of probiotics therapy for bone metabolic diseases has also been demonstrated.It suggests that intestinal microbiota may act as a potential target for the prevention and treatment of postmenopausal osteoporosis,and the application of probiotics may establisn a new and efficacious therapy.This review aims to illustrate the correlation between intestinal microbiota and postmenopausal osteoporosis as well as the critical effect of probiotics on postmenopausal osteoporosis,with a particular focus on the molecular mechanism of pathogenesis and treatment from three dimensions of intestinal microbial diversity,intestinal epithelial barrier,and host immune responses.